JP2021528471A - Adam9を標的とする免疫コンジュゲート、及び、その使用の方法 - Google Patents

Adam9を標的とする免疫コンジュゲート、及び、その使用の方法 Download PDF

Info

Publication number
JP2021528471A
JP2021528471A JP2020573007A JP2020573007A JP2021528471A JP 2021528471 A JP2021528471 A JP 2021528471A JP 2020573007 A JP2020573007 A JP 2020573007A JP 2020573007 A JP2020573007 A JP 2020573007A JP 2021528471 A JP2021528471 A JP 2021528471A
Authority
JP
Japan
Prior art keywords
seq
ala
adam9
domain
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528471A5 (cg-RX-API-DMAC7.html
Inventor
ヒックス,スチュアート・ウィリアム
ヨーダー,ニコラス・シー
バラット,バスワティ
ボンビニ,エツィオ
ディードリッヒ,グンド
ジョンソン,レスリー・エス
ルー,デリック
スクリブナー,ジュニパー・エイ
Original Assignee
イミュノジェン・インコーポレーテッド
マクロジェニクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノジェン・インコーポレーテッド, マクロジェニクス,インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2021528471A publication Critical patent/JP2021528471A/ja
Publication of JP2021528471A5 publication Critical patent/JP2021528471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020573007A 2018-06-26 2019-06-25 Adam9を標的とする免疫コンジュゲート、及び、その使用の方法 Pending JP2021528471A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862690052P 2018-06-26 2018-06-26
US62/690,052 2018-06-26
US201862691342P 2018-06-28 2018-06-28
US62/691,342 2018-06-28
US201962810703P 2019-02-26 2019-02-26
US62/810,703 2019-02-26
PCT/US2019/038992 WO2020005945A1 (en) 2018-06-26 2019-06-25 Immunoconjugates targeting adam9 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021528471A true JP2021528471A (ja) 2021-10-21
JP2021528471A5 JP2021528471A5 (cg-RX-API-DMAC7.html) 2022-07-04

Family

ID=67513726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573007A Pending JP2021528471A (ja) 2018-06-26 2019-06-25 Adam9を標的とする免疫コンジュゲート、及び、その使用の方法

Country Status (13)

Country Link
US (1) US20210275685A1 (cg-RX-API-DMAC7.html)
EP (1) EP3814378A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021528471A (cg-RX-API-DMAC7.html)
KR (1) KR20210061995A (cg-RX-API-DMAC7.html)
CN (1) CN112543770A (cg-RX-API-DMAC7.html)
AU (1) AU2019294510A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020025346A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104511A1 (cg-RX-API-DMAC7.html)
IL (1) IL279633A (cg-RX-API-DMAC7.html)
MX (1) MX2020013466A (cg-RX-API-DMAC7.html)
SG (1) SG11202012257VA (cg-RX-API-DMAC7.html)
TW (1) TWI831797B (cg-RX-API-DMAC7.html)
WO (1) WO2020005945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
JP2024512392A (ja) 2021-03-08 2024-03-19 イミュノジェン・インコーポレーテッド がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法
WO2024059263A1 (en) * 2022-09-15 2024-03-21 Immunogen, Inc. Methods for preparing maytansinoid derivatives with self-immolative peptide linkers
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
EP4692118A1 (en) * 2023-03-24 2026-02-11 Duality Biologics (Shanghai) Co., Ltd. Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途
CN122422348A (zh) * 2023-12-14 2026-07-17 四川科伦博泰生物医药股份有限公司 Adam9结合蛋白及其用途
WO2026102182A1 (en) * 2024-11-06 2026-05-15 Ossianix, Inc. A vnar-based brain shuttle for payload conjugation and gene therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2013508400A (ja) * 2009-10-21 2013-03-07 イミュノジェン・インコーポレーテッド 新規な投与レジメンおよび治療法
WO2017136623A1 (en) * 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20030091568A1 (en) 2000-04-07 2003-05-15 Jurgen Frey Inhibitors for the formation of soluble human CD23
EP1142910A1 (en) 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Inhibitors for the formation of soluble human CD23
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20060270618A1 (en) 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040092466A1 (en) 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7829277B2 (en) 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド Adam−9モジュレータ
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
KR101443214B1 (ko) 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
US8101361B2 (en) 2008-03-10 2012-01-24 National Jewish Health Markers for diagnosis of pulmonary inflammation and methods related thereto
WO2009126616A2 (en) 2008-04-07 2009-10-15 Zymogenetics, Inc. Thrombin activator compostions and methods of making and using the same
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010053539A2 (en) 2008-11-05 2010-05-14 The Texas A&M University System Methods for detecting colorectal diseases and disorders
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2789679A1 (en) 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20130130355A1 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex
IN2014CN04935A (cg-RX-API-DMAC7.html) 2011-12-31 2015-09-18 Moni Abraham Kuriakose
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
CA2897340C (en) 2013-01-09 2022-09-06 Friedrich-Alexander-Universitat Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
EP3964237B1 (en) * 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
JPWO2014168154A1 (ja) 2013-04-08 2017-02-16 三菱レイヨン株式会社 眼疾患を評価するためのマイクロアレイ及び眼疾患の評価方法
ES2902420T3 (es) 2013-05-13 2022-03-28 Univ Tufts Composiciones para el tratamiento del cáncer que expresa ADAM8
US20160138113A1 (en) 2013-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
WO2016077505A2 (en) 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
MD3558391T2 (ro) * 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2013508400A (ja) * 2009-10-21 2013-03-07 イミュノジェン・インコーポレーテッド 新規な投与レジメンおよび治療法
WO2017136623A1 (en) * 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.77, No.13, Suppl., JPN6023025415, 2017, pages 38, ISSN: 0005268667 *
CANCER RESEARCH, vol. Vol.77, No.13, Suppl., JPN6023025416, 2017, pages 37, ISSN: 0005268666 *
PROTEIN & CELL, vol. 9, no. 1, JPN6023025417, 14 October 2016 (2016-10-14), pages 33 - 46, ISSN: 0005268668 *

Also Published As

Publication number Publication date
SG11202012257VA (en) 2021-01-28
WO2020005945A1 (en) 2020-01-02
TW202019960A (zh) 2020-06-01
BR112020025346A2 (pt) 2021-05-25
US20210275685A1 (en) 2021-09-09
AU2019294510A1 (en) 2021-01-21
KR20210061995A (ko) 2021-05-28
CA3104511A1 (en) 2020-01-02
AU2019294510A8 (en) 2021-04-22
TWI831797B (zh) 2024-02-11
MX2020013466A (es) 2021-04-19
IL279633A (en) 2021-03-01
EP3814378A1 (en) 2021-05-05
CN112543770A (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
JP7611218B2 (ja) 抗cd123抗体、ならびにその複合体及び誘導体
JP7821733B2 (ja) エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
TWI783957B (zh) 靶向adam9之免疫共軛物及其使用方法
TWI831797B (zh) 靶向adam9之免疫接合物及其使用方法
TWI897855B (zh) E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
KR102434626B1 (ko) 항-b7-h3 항체 및 항체 약물 콘쥬게이트
KR20180130574A (ko) 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
KR20220113747A (ko) 항 cea 항체-엑사테칸 유사체의 접합체 및 이의 약학적 용도
JP2022529726A (ja) Anti-cd117とその使用
JP2019534267A (ja) 抗c met抗体‐細胞傷害性薬物複合体の医学的使用
TW202430557A (zh) Anti-Met抗體、抗體藥物偶聯物及其製備方法和用途
RU2830242C1 (ru) Лекарственный конъюгат производного эрибулина, способ его получения и его применение в медицине
TW202448517A (zh) 用治療性結合分子治療癌症的組合療法
HK40015128B (en) Immunoconjugates targeting adam9 and methods of use thereof
HK40015128A (en) Immunoconjugates targeting adam9 and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241017